Zanidatamab
December 6, 2022 - December 10, 2022

Antitumor Activity of Zanidatamab with Palbociclib and Fulvestrant in HER2+ Hormone-Receptor Positive (HR+) Metastatic Breast Cancer

Escrivá-de-Romani et al.